CORCEPT THERAPEUTICS INC Cost of Revenue
CORCEPT THERAPEUTICS INC (CORT) reported Cost of Revenue of $4.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC cost of goods and services sold for the quarter ending 2026-06-30 was $4.06M, a 18.29% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for the quarter ending 2026-03-31 was $2.88M, a 19.98% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for the quarter ending 2025-12-31 was $2.54M, a 13.90% decline year-over-year.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for the quarter ending 2025-09-30 was $4.60M, a 60.31% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for fiscal 2025 was $12.98M, a 19.25% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for fiscal 2024 was $10.88M, a 67.91% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for fiscal 2023 was $6.48M, a 20.35% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC cost of goods and services sold for fiscal 2022 was $5.38M, a 1.97% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.06M 10-Q · filed 2026-07-29 | $6.94M 10-Q · filed 2026-07-29 | $9.49M derived: sum of 3 quarters · filed 2026-07-29 | $14.09M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $2.88M 10-Q · filed 2026-04-30 | $5.43M derived: sum of 2 quarters · filed 2026-04-30 | $10.02M derived: sum of 3 quarters · filed 2026-04-30 | $13.46M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.14M derived: sum of 2 quarters · filed 2026-02-24 | $10.57M derived: sum of 3 quarters · filed 2026-07-29 | $12.98M 10-K · filed 2026-02-24 |
| 2025-09-30 | $4.60M 10-Q · filed 2025-11-04 | $8.03M derived: sum of 2 quarters · filed 2026-07-29 | $10.43M 10-Q · filed 2025-11-04 | $13.39M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $3.43M 10-Q · filed 2026-07-29 | $5.84M 10-Q · filed 2026-07-29 | $8.79M derived: sum of 3 quarters · filed 2026-07-29 | $11.66M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $2.40M 10-Q · filed 2026-04-30 | $5.36M derived: sum of 2 quarters · filed 2026-04-30 | $8.23M derived: sum of 3 quarters · filed 2026-04-30 | $10.75M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.82M derived: sum of 2 quarters · filed 2026-02-24 | $8.35M derived: sum of 3 quarters · filed 2026-02-24 | $10.88M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.87M 10-Q · filed 2025-11-04 | $5.39M derived: sum of 2 quarters · filed 2025-11-04 | $7.93M 10-Q · filed 2025-11-04 | $9.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.52M 10-Q · filed 2025-07-31 | $5.06M 10-Q · filed 2025-07-31 | $6.94M derived: sum of 3 quarters · filed 2026-02-24 | $8.58M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.54M 10-Q · filed 2025-05-05 | $4.41M derived: sum of 2 quarters · filed 2026-02-24 | $6.06M derived: sum of 3 quarters · filed 2026-02-24 | $7.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.52M derived: sum of 2 quarters · filed 2026-02-24 | $5.10M derived: sum of 3 quarters · filed 2026-02-24 | $6.48M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.65M 10-Q · filed 2024-10-30 | $3.22M derived: sum of 2 quarters · filed 2024-10-30 | $4.60M 10-Q · filed 2024-10-30 | $6.08M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.57M 10-Q · filed 2024-07-29 | $2.96M 10-Q · filed 2024-07-29 | $4.44M derived: sum of 3 quarters · filed 2025-02-26 | $5.78M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $1.39M 10-Q · filed 2024-05-01 | $2.87M derived: sum of 2 quarters · filed 2025-02-26 | $4.21M derived: sum of 3 quarters · filed 2025-02-26 | $5.52M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.82M derived: sum of 2 quarters · filed 2025-02-26 | $4.13M derived: sum of 3 quarters · filed 2025-02-26 | $5.38M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.34M 10-Q · filed 2023-11-01 | $2.65M derived: sum of 2 quarters · filed 2023-11-01 | $3.90M 10-Q · filed 2023-11-01 | $5.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $1.32M 10-Q · filed 2023-08-02 | $2.57M 10-Q · filed 2023-08-02 | $3.92M derived: sum of 3 quarters · filed 2024-02-15 | $5.20M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $1.25M 10-Q · filed 2023-05-03 | $2.60M derived: sum of 2 quarters · filed 2024-02-15 | $3.88M derived: sum of 3 quarters · filed 2024-02-15 | $5.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $2.63M derived: sum of 2 quarters · filed 2024-02-15 | $4.01M derived: sum of 3 quarters · filed 2024-02-15 | $5.28M 10-K · filed 2024-02-15 |
| 2021-09-30 | $1.27M 10-Q · filed 2022-11-03 | $2.66M derived: sum of 2 quarters · filed 2022-11-03 | $3.93M 10-Q · filed 2022-11-03 | $5.18M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.38M 10-Q · filed 2022-08-04 | $2.65M 10-Q · filed 2022-08-04 | $3.91M derived: sum of 3 quarters · filed 2023-02-28 | $5.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.27M 10-Q · filed 2022-05-05 | $2.52M derived: sum of 2 quarters · filed 2023-02-28 | $3.74M derived: sum of 3 quarters · filed 2023-02-28 | $4.97M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.47M derived: sum of 2 quarters · filed 2023-02-28 | $3.70M derived: sum of 3 quarters · filed 2023-02-28 | $5.58M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.22M 10-Q · filed 2021-11-03 | $2.45M derived: sum of 2 quarters · filed 2021-11-03 | $4.33M 10-Q · filed 2021-11-03 | $5.76M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $1.23M 10-Q · filed 2021-07-29 | $3.11M 10-Q · filed 2021-07-29 | $4.55M derived: sum of 3 quarters · filed 2022-02-15 | $6.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $1.88M 10-Q · filed 2021-05-06 | $3.31M derived: sum of 2 quarters · filed 2022-02-15 | $4.76M derived: sum of 3 quarters · filed 2022-02-15 | $6.14M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $2.89M derived: sum of 2 quarters · filed 2022-02-15 | $4.26M derived: sum of 3 quarters · filed 2022-02-15 | $5.50M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.45M 10-Q · filed 2020-11-03 | $2.83M derived: sum of 2 quarters · filed 2020-11-03 | $4.07M 10-Q · filed 2020-11-03 | $5.65M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $1.38M 10-Q · filed 2020-08-04 | $2.62M 10-Q · filed 2020-08-04 | $4.20M derived: sum of 3 quarters · filed 2021-02-23 | $5.50M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $1.24M 10-Q · filed 2020-05-04 | $2.82M derived: sum of 2 quarters · filed 2021-02-23 | $4.13M derived: sum of 3 quarters · filed 2021-02-23 | $5.28M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $2.89M derived: sum of 2 quarters · filed 2021-02-23 | $4.04M derived: sum of 3 quarters · filed 2021-02-23 | $5.21M 10-K · filed 2021-02-23 |
| 2018-09-30 | $1.31M 10-Q · filed 2019-11-07 | $2.46M derived: sum of 2 quarters · filed 2019-11-07 | $3.64M 10-Q · filed 2019-11-07 | $4.79M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $1.15M 10-Q · filed 2019-08-01 | $2.33M 10-Q · filed 2019-08-01 | $3.48M derived: sum of 3 quarters · filed 2020-02-24 | $4.46M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $1.17M 10-Q · filed 2019-05-09 | $2.33M derived: sum of 2 quarters · filed 2020-02-24 | $3.31M derived: sum of 3 quarters · filed 2020-02-24 | $4.08M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $2.13M derived: sum of 2 quarters · filed 2020-02-24 | $2.91M derived: sum of 3 quarters · filed 2020-02-24 | $3.55M 10-K · filed 2020-02-24 |
| 2017-09-30 | $976.00K 10-Q · filed 2018-11-02 | $1.75M derived: sum of 2 quarters · filed 2018-11-02 | $2.40M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | $775.00K 10-Q · filed 2018-08-09 | $1.42M 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $2.06M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |